Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 195

Results For "global"

4792 News Found

Windlas Biotech’s new injectable facility receives GMP certification
News | January 10, 2025

Windlas Biotech’s new injectable facility receives GMP certification

The certification marks a new chapter in Windlas Biotech’s growth trajectory,


ProBioGen expands protein and viral manufacturing to drive continued growth
News | January 09, 2025

ProBioGen expands protein and viral manufacturing to drive continued growth

This strategic move aims to address the increasing global demand for biologics, enhancing ProBioGen's ability to support partners from cell line development t


Lupin receives EIR from USFDA for Pithampur Unit-1 Facility with VAI Classification
Drug Approval | January 09, 2025

Lupin receives EIR from USFDA for Pithampur Unit-1 Facility with VAI Classification

The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection of the facility from September 16 to September 27, 2024


Ayush onsite to enrich experience at Mahakumbh: Prataprao Jadhav
News | January 09, 2025

Ayush onsite to enrich experience at Mahakumbh: Prataprao Jadhav

Services like 24/7 Ayush Multi-OPD clinics, mobile healthcare units, free distribution of Ayush medicines, and yoga camps are there for all visitors


Evonik partners with South Korean ST Pharm to increase its offerings for RNA and nucleic acid delivery
News | January 09, 2025

Evonik partners with South Korean ST Pharm to increase its offerings for RNA and nucleic acid delivery

Increases speed to market for drug developers working on nucleic acid therapeutics


GEON Performance Solutions acquires Foster Corporation
News | January 09, 2025

GEON Performance Solutions acquires Foster Corporation

Acquisition expands high-value medical platform


Elinzanetant meets all primary and secondary endpoints in Phase III study OASIS 4 for treatment of vasomotor symptoms caused by breast cancer treatments
Clinical Trials | January 09, 2025

Elinzanetant meets all primary and secondary endpoints in Phase III study OASIS 4 for treatment of vasomotor symptoms caused by breast cancer treatments

The study also met all secondary endpoints with a reduction in severity of VMS at weeks 4 and 12, a reduction in frequency of VMS at week 1 as well as improvements in sleep disturbances and menopause related quality of life


HMPV update: States advised to strengthen awareness among masses regarding preventive measures
Healthcare | January 08, 2025

HMPV update: States advised to strengthen awareness among masses regarding preventive measures

Data from IDSP does not indicate any unusual rise in ILI/SARI cases anywhere in the country


Biocon Biologics embarks on a three-stage strategic journey
News | January 08, 2025

Biocon Biologics embarks on a three-stage strategic journey

Successfully transformed the organization from a two-country operation focused on development and manufacturing to a fully integrated company with a strong commercial engine bringing us closer to patients in over 120 countries


Sentynl Therapeutics receives USFDA acceptance and priority review of new drug application for CUTX-101 product candidate for treatment of Menkes disease
Drug Approval | January 07, 2025

Sentynl Therapeutics receives USFDA acceptance and priority review of new drug application for CUTX-101 product candidate for treatment of Menkes disease

Menkes disease is a rare X-linked recessive pediatric disease caused by gene mutations of the copper transporter ATP7A